T
Telomir Pharmaceuticals, Inc.
Period
FY 2025
Revenue
—
Net Income
$-10.40M
Total Assets
$7.34M
Equity
$5.90M
Shares Out
68.77M
Op. Cash Flow
$-3.70M
Business
Telomir Pharmaceuticals is a preclinical-stage biotechnology company developing small-molecule therapeutics targeting upstream biological drivers of aging and age-related diseases. The company's lead candidate, Telomir-1, is an orally administered small molecule designed to modulate intracellular metal balance and reduce oxidative stress across multiple disease pathways. Telomir-1 is being evaluated preclinically for Wilson's disease, Type 2 diabetes, age-related macular degeneration, cancer, and progeria.
Summary from 10-K filed 2026-03-17
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Revenues | — | — | — | — | |
| General and administrative expenses | 8 | 10 | 600,192 | 20,941 | |
| Related party travel costs | — | 370,500 | 2 | — | |
| Research and development expenses | 2 | 2 | 2 | 833,206 | |
| Total operating costs | 11 | 12 | 4 | 854,147 | |
| Interest income | 125,644 | 48,000 | — | — | |
| Interest expense | — | −4 | −2 | — | |
| Net loss | −10 | −17 | −13 | −854,147 | |
| Basic loss per share | −0.33 | −0.56 | 0.48 | −0.03 | |
| Diluted loss per share | −0.33 | −0.56 | 0.48 | −0.03 | |
| Basic weighted average common stock shares outstanding | 32 | 30 | 27 | 27 | |
| Diluted weighted average common stock shares outstanding | 32 | 30 | 27 | 27 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 7 | 1 | 1,231 | 1,419 | — | |
| Prepaid expenses | 54,691 | 57,874 | 713 | — | — | |
| Total current assets | 7 | 1 | 435,225 | 48,730 | — | |
| Total assets | 7 | 1 | 5 | 48,730 | — | |
| Trade accounts payable and accrued liabilities | 536,769 | 587,536 | 707,187 | 404,221 | — | |
| Due to officer | 155,518 | — | — | — | — | |
| Accrued compensation - officer | 417,470 | — | — | — | — | |
| Due to related parties | 318,234 | 93,432 | 527,377 | — | — | |
| Total current liabilities | 1 | 680,968 | 1 | 986,008 | — | |
| Total liabilities | 1 | 680,968 | 1 | 986,008 | — | |
| Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding. | — | — | — | — | — | |
| Common Stock, no par value; 300,000,000 shares authorized, 34,380,971 and 29,762,671 shares issued and outstanding at December 31, 2025 and 2024, respectively. | — | — | — | — | — | |
| Additional paid-in capital | 47 | 31 | 18 | 55,000 | — | |
| Accumulated deficit | −41 | −31 | −14 | −992,278 | — | |
| Total stockholders equity | 6 | 600,000 | 3 | −937,278 | −138,131 | |
| Total liabilities and stockholders equity | 7 | 1 | 5 | 48,730 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Stock-based compensation expense | 5 | 7 | — | — | |
| Issuance of common stock for services | 840,000 | — | — | — | |
| Credit loss expenses - loan due from related party | — | 130,000 | — | — | |
| Amortization of debt issuance costs | — | 4 | 2 | — | |
| Prepaid expenses | 3,183 | −57,160 | −713 | — | |
| Trade accounts payable and accrued liabilities | −50,767 | 183,629 | 114,556 | 385,486 | |
| Due to related parties | 224,802 | — | — | — | |
| Accrued compensation - officer | 417,470 | — | — | — | |
| Net cash used in operating activities | −4 | −5 | −4 | −468,661 | |
| Payments under related party line of credit | — | −101,000 | — | — | |
| Repayments to related party | — | −433,945 | 2 | 462,391 | |
| Repayment from officer | 155,518 | — | — | — | |
| Proceeds from warrant exercise | — | 37,300 | — | — | |
| Proceeds from sale of common stock, related party | 3 | — | — | — | |
| Net proceeds from sale of common stock | 7 | 7 | — | — | |
| Net cash provided by financing activities | 10 | 6 | 4 | 470,080 | |
| Net change in cash | 6 | 1 | −188 | 1,419 | |
| Cash paid for interest | — | — | — | — | |
| Cash paid for income tax | — | — | — | — | |
| Deferred offering costs charged to additional paid-in capital | — | 303,281 | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Telomir Pharmaceuticals, Inc.'s CIK number?
Telomir Pharmaceuticals, Inc.'s SEC CIK number is 0001971532 (1971532). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Telomir Pharmaceuticals, Inc.'s SEC filings?
All of Telomir Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.